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Abstract
Background: Long non-coding RNA (lncRNA) H19 has been reported to involve in many kinds of human cancers
and functions as an oncogene. Our previous study found that H19 was over-expressed in gallbladder cancer (GBC)
and was shown to promote tumor development in GBC. However, the competing endogenous RNA (ceRNA)
regulatory network involving H19 in GBC progression has not been fully elucidated. We aim to detect the role of
H19 as a ceRNA in GBC.
Methods and Results: In this study, the expression of H19 and miR-342-3p were analyzed in 35 GBC tissues and
matched normal tissues by using quantitative polymerase chain reaction (qRT-PCR). We demonstrated H19 was
overexpressed and negatively correlated with miR-342-3p in GBC. By dual-luciferase reporter assays, RNA-binding
protein immunoprecipitation (RIP) and RNA pull-down assays, we verified that H19 was identified as a direct target
of miR-342-3p. QRT-PCR and Western-blotting assays demonstrated that H19 silencing down-regulated, whereas
over-expression enhanced the expression of miR-342-3p targeting FOXM1 through competitively ‘sponging’ miR-
342-3p. Furthermore, transwell invasion assays and cell cycle assays indicated that H19 knockdown inhibited both
cells invasion and proliferation, but this effects was attenuated by co-transfection of siRNA-H19 and miR-342-3p
inhibitor in GBC cells. In vivo, tumor volumes were decreased significantly in H19 silenced group compared to the
control group, but was attenuated by co-transfection of shRNA-H19 and miR-342-3p inhibitor, which were stablely
constructed through lenti-virus vector.
Conclusion: Our results suggest a potential ceRNA regulatory network involving H19 regulates FOXM1 expression
by competitively binding endogenous miR-342-3p in GBC. This mechanism may contribute to a better understanding
of GBC pathogenesis and provides potential therapeutic strategy for GBC.
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Background
Gallbladder cancer (GBC) is the most common biliary
tract cancer and the fifth most common gastrointes-
tinal malignancy [1]. It is estimated that there were
10,910 new cases and 3,700 deaths from gallbladder
(and other biliary) cancer in the United States in 2015
(http://www.cancer.gov/). Major advances in cancer
biology had led to better understanding the mechanism
of GBC tumorigenesis and then led to novel thera-
peutic methods [2–4]. A Phase II study on gemcitabine,
oxaliplatin in combination with panitumumab, a new
drug inhibiting Epidermal Growth Factor Receptor
(EGFR), has shown encouraging efficacy in unresectable
biliary tract and GBC [5]. However, EGFR expression
ranges from 39 ~ 85 % in GBC patients, and it was not
a specific marker in gallbladder marker [6, 7]. Thus, it
is extreme urgency to find novel molecular target and
provide potential therapeutic strategy for GBC.
Long non-coding RNAs (LncRNAs) are RNAs longer
than 200 nucleotides [8]. Recently, lncRNAs had been
reported to be involved in genetic and epigenetic
regulation and post-transcriptional regulation [9–11].
Some lncRNAs had been reported to be functioned as
prognostic marker [12, 13]. Mechanism studies about
the biological role of lncRNA in caners also been pro-
posed by some research groups [14, 15]. In GBC,
HOX transcript antisense intergenic RNA (HOTAIR),
metastasis-associated lung adenocarcinoma transcript
1 (MALAT1) and Colon cancer-associated transcript-1
(CCAT1) had been proved to be important for GBC
progression [16–18].
LncRNA H19 is located at 11p15.5 locus, whose ex-
pression is high in fetus but decreased after birth.
These favorable characteristics enable its function as
a genetic biomarker [19]. Mutation of H19 in mouse
zygotes causes prenatal lethality, indicating its vital
role in growth and development [20]. New progress
in understanding the intrinsic mechanisms of lncRNA
including competitive endogenous RNA(ceRNA) para-
digm [21]. MicroRNAs (miRNAs) were well-accepted
regulators in cancer and other diseases [22–25].
LncRNA, such as H19, act as a molecular sponge
inhibiting miRNA let-7 [26]. H19 promotes epithelial
to mesenchymal transition by functioning as miRNA
sponges in colorectal cancer [27]. Our previous study
found H19 is upregulated in GBC, and H19 promoted
the GBC cells proliferation by AKT2 [28, 29], these
results further enhanced our research interests for
the role H19 involving in ceRNA regulatory network
in GBC progression.
In this study, we demonstrated that H19 modulated
FOXM1 expression by competitively ‘sponging’ to miR-
342-3p, which led to promote cells proliferation and
invasion in GBC cells.
Methods
Patient samples
Thirty-five gallbladder carcinoma tissues and pair-
matched normal gallbladder tissues in this study (collected
postoperatively from January 2009 to March 2012) were
obtained from patients who underwent radical resections
at Xinhua Hospital (Shanghai Jiao Tong University School
of Medicine, Shanghai, China) and Eastern Hepatobiliary
Surgical Hospital and Institute (The Second Military
University, Shanghai, China). Samples were snap-frozen in
liquid nitrogen and stored at −80 °C before RNA isolation
and qRT-PCR analysis. None of the patients recruited to
this study received any pre-operative treatments. GBC
patients were staged according to the TNM staging system
(the seventh edition) of the American Joint Committee
on Cancer staging system. Complete clinic-pathological
follow-up data of the GBC patients were collected. The
study methodology conformed to the standard set by the
Declaration of Helsinki and was approved by the Human
Ethics Committee of Xinhua Hospital at Shanghai Jiao
Tong University (Shanghai, China). All patients had
signed inform consent forms.
Cell culture
Three human GBC cell lines (GBC-SD, EHGB-1 and
NOZ) were used in this study. GBC-SD was purchased
from Cell Bank of the Chinese Academy of Science
(Shanghai, China). NOZ was purchased from the Health
Science Research Resources Bank (Osaka, Japan).
EHGB-1 was a generous gift from Eastern Hepatobiliary
Surgical Hospital and Institute, The Second Military
University, Shanghai, China. The cell lines were cultured
in Dulbecco’s modified Eagle’s medium (Gibco BRL,
Grand Island, NY, USA), containing 10 % fetal bovine
serum (FBS, HyClone, Invitrogen, Camarillo, CA, USA),
100 μg/ml penicillin and 100 μg/ml streptomycin (Invitro-
gen, Carlsbad, CA, USA). Cells were maintained in a
humidified incubator at 37 °C in the presence of 5 % CO2.
RNA extraction and qRT-PCR analysis
Total RNA from tissues and cells was extracted using
Trizol reagent (TAKARA). RNA was reverse transcribed
into cDNAs using the Primer-Script one step RT-PCR
kit (TAKARA, Dalian, China). The cDNA template was
amplified by real-time RT-PCR using the SYBR Premix
Dimmer Eraser kit (TAKARA), which including U6
aliquot. Gene expression in each sample was normalized
to GADPH or U6 expression. The primer sequences used
were as follows: GAPDH, forward: 5’-GTCAACGGATTT
GGTCTGTATT-3’ and reverse: 5’-AGTCTTCTGGGTGG
CAGTGAT-3’; H19, forward: 5’-TTCAAAGCCTCCACG
ACTCT-3’ and reverse: 5’-: GCTCACACTCACGCACAC
TC-3’. FOXM1, forward: 5’-GAGACCTGTGATGGTGAG
GC-3’ and reverse: 5’-ACCTTAACCTGTCGCTGCTC-3’.
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Real-time PCR reactions were performed using the
ABI7500 system (Applied Biosystems, Carlsbad, CA,
USA). The real-time PCRs were performed in triplicate.
Relative expression fold change of mRNAs was calcu-
lated by the 2−ΔΔCt method.
Cell transfection
MiR-342-3p mimic or negative control mimic and has-
miR-342-3p inhibitor or negative control inhibitor were
purchased from Genepharma, Shanghai, China. The
siRNAs specifically targeting H19 were synthesized by
Genepharma, Shanghai, China. The siRNA sequences
for H19 were si-H19-1, 5’-CCAACAUCAAAGACAC
CAUdTdT-3’, si-H19-2, 5’-UAAGUCAUUUGCACUG
GUUdTdT-3’, and si-H19-3, sense 5’-CCCACAACA
UGAAAGAAACTT-3’, and antisense: 5’-AUU UCU UUC
AUG UUG UGG GTT-3’. SiRNAs specifically targeting
FOXM1 were synthesized by Genepharma, Shanghai,
China. The siRNA sequences for FOXM1 were si-FOXM1-
1, 5’-CUCUUCUCCCUCAGAUAUA-3’, and si-FOXM-2,
5’-CCAGAGAGATGGACTGACA-3’. Transfections were
performed using the Lipofectamine 2000 kit (Invitrogen)
according to the manufacturer’s instructions.
Luciferase reporter assay
Human HEK293T cells (2.0 assays with a Molecular
Imager) were co-transfected with 150 ng of either empty,
pmir-GLO-NC, pmir-GLO-H19-wt or pmirGLO-H19-
mut (Sangon biotech,China). Two ng of pRL-TK (Pro-
mega, Madison, WI, USA) were also co-transfected with
miR-342-3p mimic or miRNA NC into HEK293T cells
by using Lipofectamie 2000 (Invitrogen, USA). The rela-
tive luciferase activity was normalized to Renilla luciferase
activity 48 h after transfection. Transfection was repeated
in triplicate.
RNA pull-down assay
To determine whether H19 is associated with the RISC
complex, we performed RNA pull-down assay using biotin
labeled H19 as a probe and then detected Ago2 from the
pellet by western-blotting and miR-342-3p by qRT-PCR.
The resultant plasmid DNA was linearized with restriction
enzyme NotI. Biotin-labeled RNAs were in vitro tran-
scribed with the Biotin RNA Labeling Mix (Roche Diag-
nostics, Indianapolis, IN, USA) and T7 RNA polymerase
(Roche, Basel, Switzerland), treated with RNase-free
DNase I (Roche) and purified with the RNeasy Mini Kit
(Qiagen, Inc., Valencia, CA, USA). Cell extract (2 μg) was
mixed with biotinylated RNA (100 pmol). Washed Strep-
tavidin agarose beads (100 ml) were added to each binding
reaction and further incubated at room temperature for
1 h. Beads were washed briefly three times and boiled
in SDS buffer, and the retrieved protein was detected
by standard western blot technique. The Ago2
antibodies used for pull-down were purchased from
Abcam (Cambridge, MA, USA). The co-precipitated
RNAs were detected by RT-PCR. Total RNAs and con-
trols were also assayed to demonstrate that the detected
signals were from RNAs specifically binding to Ago2.
RNA immunoprecipitation (RIP)
RIP assay was performed as described previously [18],
normal mouse IgG (Millipore) and SNRNP70 (Millipore)
were used as negative control and positive control,
respectively. The co-precipitated RNAs were detected by
qRT-PCR. Total RNAs (input controls) and IgG were
assayed simultaneously to demonstrate that the detected
signals were the result of RNAs specifically binding to
Ago2 (Cell signaling, USA).
Immunohistochemistry (IHC)
Tumor specimens from nude mice were fixed in 4 %
paraformaldehyde and then embedded in paraffin. Sec-
tions were used for the analysis of FOXM1 (1:100, Santa
Cruz Biotechnology, Santa Cruz, CA). The samples were
then incubated at 4 °C overnight with primary antibodies
against FOXM1,and then treated with secondary anti-
body for 30 min and stained with diaminobenzidine
(DAB) until brown granules appeared. Sections were
blindly evaluated by two pathologists with light mi-
croscopy. Semi-quantitative of IHC was performed as
described previously [30].
Western-blotting
Western blot analysis to assess FOXM1 (1:500, Santa
Cruz Biotechnology, Santa Cruz, CA) and GADPH
(1:1000, Proteintech, China) expression was carried out
as described previously [18]. GADPH primary antibody
was purchased from Sigma (St. Louis, MO, USA).
FOXM1 antibody was purchased from Santa Cruz
Biotechnology, Inc. USA.
Flow cytometric analysis
Cells transfected with desired plasmid or negative con-
trol were plated in six-well plates. After 48 h incubation,
the cultures were incubated with propidium iodide for
30 min in the dark. Cultures were collected and analyzed
for cell cycle using a flow cytometer (FACS Calibur, BD
Biosciences, San Jose, CA, USA) after propidium iodide
staining. Data were expressed as percentage distribution
of cells in G0/G1, S and G2/M phases of the cell cycle.
Cell invasion assays
For the invasion assays, 48 h after transfection, 2 × 105
cells in serum-free media were placed into the upper
chamber of an insert (8.0 μm, Millipore, Temecula, MA,
USA) precoated with Matrigel (Sigma). The chambers
were then incubated for 24 h in culture medium with
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10 % FBS in the bottom chambers before examination.
The cells on the upper surface were scraped and washed
away, whereas the invaded cells on the lower surface
were fixed and stained for 2 h. Finally, invaded cells were
counted under a microscope and the relative number
was calculated. Experiments were independently repeated
three times.
Xenograft mouse model
NOZ cells (1× 106) stably expressing control shRNA or
H19 shRNA, or miR-342-3p inhibitor (an anti-miR-342-
3p Oligonucleotides, purchased from Hanbio, Shanghai,
China) or H19 shRNA +miRNA-342-3p inhibitor were
subcutaneously injected into either side of flank area of
3-week-old Male nude mice (n = 4 mice per group).
Tumor volumes were measured (0.5 × length × width2)
in mice on a weekly basis. After 4 weeks, mice were
sacrificed, and tumors were excised and subjected to
immune-histochemical analysis for FOXM1 expression.
All animal experiments were performed in animal labora-
tory center of XinHua Hospital and in accordance with
the Guide for the Care and Use of Laboratory Animals
Fig. 1 Expression of H19 in GBC and its effect on miR-342-3p. a Expression of H19 in 35 pair samples of GBC and adjacent normal tissues.
The expression of H19 was normalized to GADPH, differences between GBC tissues and normal gallbladder tissues were compared by Paired
Sample T test method (n = 35, P < 0.05). b H19 was knockdown by three siRNA targeting H19 (P < 0.05). c Expression level of H19 in GBC-SD
cells after infection of lenti-virus vector which containing full-length of H19 was detected by qRT-PCR (P < 0.05). d–e The expression level
of miR-342-3p after H19 silencing in NOZ and EHGB-1 cells was detected by qRT-PCR (P < 0.05). f The expression of miR-342-3p after over-
expression of H19 was detected by qRT-PCR in GBC-SD cells (P < 0.05). g The expression of H19 after transfected of miR-342-3p inhibitor or
mimic. All data were represented as the mean ± S.D. from three independent experiments, **P < 0.05
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published by the US National Institutes of Health (NIH
publication number 85–23, revised 1996). The study
protocol was approved by the Animal Care and Use com-
mittee of Xinhua Hospital (approval ID: 2014041).
Statistics analysis
All statistical analyses were performed using SPSS 13.0
(SPSS, Chicago, IL, USA). The expression differences be-
tween GBC and matched normal tissues were analyzed
using paired samples t-test. Pearson’s coefficient correl-
ation was used for expression correlation assay. The ex-
pression differences between the expression changes
after transfection, S-phase fraction and invasion assay
were analyzed using independent samples t-test. P-values
were two-sided and a value of 0.05 was considered to be
statistically significant.
Results
Identification of potential H19 targeting miRNAs
Previous study demonstrated H19 was overexpressed in
GBC [29]. By expanding the cases of GBC specimens and
paired normal tissues, we further confirmed that H19 was
up-regulated in GBC tissues compared with adjacent nor-
mal tissues (Fig. 1a, P < 0.05). Based on previous study [29],
H19 had the highest expression in NOZ cells measured in
four GBC cell lines (SGC-996, GBC-SD, EHGB-1 and
NOZ). NOZ cells was selected for H19 knockdown by
three siRNA (Fig. 1a) and the efficient silencing of si-H19-1
was used in later experiments and GBC-SD cells were se-
lected for over-expression experiment due to their relatively
low H19 expression and easy-to-transfect feature (Fig. 1c).
A cohort of 20 potential miRNAs that could interact
with H19 was predicted through starbase 2.0 and Miranda
(http://starbase.sysu.edu.cn/ and http://www.microrna.org/)
(Table 1). To search for specific target miRNA of H19 in
GBC cells, H19 was knockdown in NOZ cells and then the
miRNAs predicted above were measured by qRT-PCR in
NOZ cells. The efficiency of interference of H19 in NOZ
cells was confirmed by qRT-PCR (Fig. 1a). In Table 1, there
were two miRNAs which were up-regulated more than
2.5-fold in response to H19 silencing. We focused on
miR-342-3p, which had the greatest fold-change. MiR-
342-3p expression levels were markedly increased after
silencing H19 in NOZ and EHGB-1 cells (P < 0.05)
(Fig. 1d–e). On the contrary, miR-342-3p expression was
decreased significantly after over-expression of H19 in
GBC-SD cells (P < 0.05) (Fig. 1c and f). However, the ex-
ogenous miR-342-3p inhibitors or mimics did not alter
the expression of H19 (Fig. 1g).
The potential mechanism of the negative regulation of
miR-342-3p by H19
Furthermore, we detected that miR-342-3p was down-
regulated in GBC tissues compared to adjacent normal
tissues (P < 0.05), the expression of miR-342-3p was nor-
malized to U6 (Fig. 2a). In addition, the expression level of
H19 was significant negatively correlation with miR-342-
3p (R = −0.403, P < 0.05) (Fig. 2b). These results indicated
that miR-342-3p might have an interaction with H19.
To explore whether miR-342-3p was targeted and
directly bound to H19, fragments of wild-type and
mutated H19 cDNA sequence containing the putative
miR-342-3p recognition site (predicted in starbase 2.0)
(Fig. 2c) was cloned. Dual reporter luciferase was per-
formed in HEK293T cells. Dual luciferase reporter assay
results indicated that miR-342-3p mimic significantly
decreased the luciferase activities of pmir-Glo-H19-wt
(49 %) but not pmir-Glo-H19-mut (Fig. 2d).
MiRNAs and siRNAs guided Argonaute proteins (Ago
proteins including Ago2) to silence mRNA expression
through RNA-Induced Silencing Complex (RISC) [31–33].
Then we conducted pull-down assay to explore whether
H19 functioned through RISC complex via interaction
with Ago2. We showed that H19 probe harbored the
Ago2 protein and detected the expression of miR-342-
3p in the same pellet, the antisense strand of H19
probe was used as negative control (Fig. 2e and f ). We
also demonstrated that H19 was preferentially enriched
in Ago2-containing beads compared with the beads
Table 1 QRT-PCR verified the fold change expression of
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harboring control immunoglobulin G (IgG) antibody.
U1 small nuclear ribonucleoprotein 70 kDa (SNRNP70),
a gene coding SNRNP70 protein associated with U1
spliceosomal RNA [34] was used as positive control
(Fig. 2g). These results suggested that H19 directly
targeted miR-342-3p.
H19 modulated expression of endogenous miR-342-3p
targets FOXM1
FOXM1 was a well-accepted oncogene that is targeted
by miR-342-3p in cervical cancer [35]. We next verified
whether H19 modulated the expression of FOXM1 by
targeting miR-342-3p in GBC cells. Compared to the
control group, the RNA and protein levels of FOXM1
were down-regulated after H19 silencing in NOZ and
GBC-SD cells and up-regulated by transfecting with miR-
342-3p inhibitors; but in the group of co-transfecting with
miR-342-3p inhibitor and siRNA-H19, the modulating
effects of H19 on FOXM1 were diminished (Fig. 3a–d).
Similarly, the RNA and protein levels of FOXM1 were
both increased after cells transfected by overexpression
H19 in GBC-SD, however, the effects were counteracting
after co-transfection of H19 plasmids and miR-342-3p
mimic (Fig. 3e and f).
FOXM1 promoted cell invasion and cell cycle in GBC cells
To investigate the functional effects of FOXM1 on GBC
cells, we measured the RNA levels of FOXM1 in GBC
tissues and their matched normal tissues via qRT-PCR.
We found that FOXM1 was up-regulated in GBC tissues
(Fig. 4a). After FOXM1 silencing, the number of invasive
cells was markedly decreased compared to the control
group (Fig. 4b–d). Cell cycle analysis indicated that
NOZ cells were arrested in G0/G1-phase and the cells
number in S-phase was significantly decreased after
FOXM1 knockdown (Fig. 4e and f ).
Fig. 2 MiR-342-3p was a target of H19. a Expression level of miR-342-3p in pair samples of GBC and normal tissues was detected by qRT-PCR
(n = 35, P < 0.05). The expression of miR-342-3p was normalized to U6. b Pearson’s correlation was used for correlation analysis between the
expression of H19 mRNA and miR-342-3p mRNA (R = −0.403, P < 0.05). c Representation the H19 and miR-342-3p binding site by miRanda
(http://www.microrna.org/). d Luciferase activity in HEKT293 cells cotransfected with miR-342-3p mimic and luciferase reporters containing
control vector, pmir-Glo-H19-wt and pmir-Glo-H19-mut (P < 0.05). e Pull-down assay was conducted using Biotin-labeled H19 probe and detected
the AGO2 expression by western-blotting assays. Antisense of the H19 probe was used as negative control. f Pull-down assay was conducted using
Biotin-labeled H19 probe and miR-342-3p level was detected in the substrate of pull-down assay by qRT-PCR, antisense of the H19 probe was used
as negative control. g H19 mRNA level was detected in the substrate of RIP assay by qRT-PCR. All data were represented as the mean ± S.D. from
three independent experiments, **P < 0.05
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H19/miR-342-3p/FOXM1 axis on cell invasion and cell
cycle in GBC cells
We continued to explore the effects of H19/miR-342-
3p/FOXM1 axis on invasion and cell cycle in GBC cells.
Initially, compared to the control group, knockdown of
H19 decreased the number of invasive cells in NOZ and
GBC-SD cells, but was reversed by co-transfection of
siRNA-H19 and miR-342-3p inhibitor simultaneously
(Fig. 5a–d). In cell cycle assay in NOZ and GBC-SD cells,
knockdown of H19 induced cell cycle arrest in G0/G1
phase, but was reversed by co-transfection of siRNA-H19
and miR-342-3p inhibitor (Fig. 6a–d).
H19 oncogenic activity is in part through negative
regulation of miR-342-3p in vivo
To verify our in vitro findings, we established an in vivo
xenograft model in nude mice. Four lenti-virus con-
structed cells including lv-control, lv-sh-H19, lv-miR-
342-3p inh and lv-miR-342-3p inh + lv-sh-H19 were well
cultured and were injected subcutaneously. Tumors
were allowed to form and grow for 4 weeks (n = 4 for
each group). Tumor volumes were measured weekly. At
the end of the fourth weeks, the mice were sacrificed
and tumors excised, we found that H19 knockdown sig-
nificantly reduced the tumor volume of NOZ cells when
compared with control group. Lv-miR-342-3p inhibitor
significantly increased the oncogenic ability of NOZ
cells. Simultaneous knockdown of H19 and inhibited
miR-342-3p had no impact on tumor formation (Fig. 7a
and b). Immuno-histochemical (IHC) was used to detect
the expression of FOXM1 in xenograft tumor. In con-
sistent with in vitro results, knockdown of H19 markedly
decreased the protein expression level of FOXM1, and
inhibiting miR-342-3p significantly up-regulated FOXM1
expression (Fig. 7c). Semi-quantitative of IHC was also
summarized in Fig. 7d.
To sum up, a ceRNA model was proposed to
summarize H19/miR-342-3p/FOXM1 pathway (Fig. 8).
H19 negatively regulated miR-342-3p in GBC, through
binding to miR-342-3p directly. In addition, we found
that miR-342-3p targeted FOXM1 and negatively reg-
ulated FOXM1 expression, indicating that H19 could
influence the expression of FOXM1 in GBC through
miR-342-3p (Fig. 8).
Fig. 3 H19 modulated expression of endogenous miR-342-3p targeting FOXM1. a-b The mRNA levels and protein levels of FOXM1 in NOZ cells
transfected with si-NC, si-H19, miR-342-3p inhibitor, and si-H19 +miR-342-3p inhibitor. c-d The mRNA levels and protein levels of FOXM1 in GBC-
SD cells transfected with si-NC, si-H19, si-H19 +miR-342-3p inhibitor, and miR-342-3p inhibitor. e-f The mRNA levels and protein levels of FOXM1
in GBC-SD cells transfected with pLv-CMV, miR-342-3p mimic, pLv-CMV-H19, miR-342-3p mimic + pLv-CMV-H19. All data were represented as the
mean ± S.D. from three independent experiments, **P < 0.05
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Fig. 4 FOXM1 promoted cell invasion and cell cycle in GBC cells. a RNA expression level of FOXM1 and normal tissues was detected by qRT-PCR
in GBC tissues (n = 35, P < 0.05). The expression of FOXM1 was normalized to GADPH. b The expression of FOXM1 after knockdown was detected
in NOZ cell by western-blotting assays. c-d cells invasion ability and invasive cells number were detected after FOXM1 knockdown in NOZ cell
(P < 0.05). e-f Cell cycle was analyzed after knockdown of FOXM1 in NOZ cell. All data were represented as the mean ± S.D. from three independent
experiments, **P < 0.05
Fig. 5 H19/miR-342-3p/FOXM1 axis on cell invasion in GBC cells. a-b Cell invasion ability and invasive cells number were detected by transfecting
si-NC, siH19, miR-342-3p inhibitor, and siH19+ miR-342-3p inhibitor into NOZ cells (P < 0.05). c-d Cell invasion ability and invasive cells number
were detected by transfecting si-NC, siH19, miR-342-3p inhibitor, and siH19+ miR-342-3p inhibitor into GBC-SD cells (P < 0.05). All data were
represented as the mean ± S.D. from three independent experiments, **P < 0.05
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Fig. 6 H19/miR-342-3p/FOXM1 axis on cell cycle in GBC cells. a-b cell cycle were detected by transfecting si-NC, siH19, miR-342-3p inhibitor and
siH19+ miR-342-3p inhibitor into NOZ cells (P < 0.05). c-d Cell cycle was detected by transfecting si-NC, siH19, miR-342-3p inhibitor and siH19+
miR-342-3p inhibitor into GBC-SD cells (P < 0.05). All data were represented as the mean ± S.D. from three independent experiments, **P < 0.05
Fig. 7 H19 oncogenic activity is in part through negative regulation of miR-342-3p in vivo (a) Representation picture of tumor formation of xonograft
in nude mice in lv-control, lv-shRNA-H19, lv-miR-342-3p inhibitor and lv-shRNA-H19+ miR-342-3p inhibitor group, respectively (each group n = 4). b
Summery of tumor volume of mice which were measured in every week in lv-control, lv-shRNA-H19, lv-miR-342-3p inhibitor and lv-shRNA-H19+ miR-
342-3p inhibitor group, respectively. c Representation of FOXM1 expression in xenografts tumor using IHC method in lv-control, lv-shRNA-H19, lv-miR-
342-3p inhibitor and lv-shRNA-H19+ miR-342-3p inhbitor group, respectively. d Statistical analyses of IHC results in xenograft tumor in lv-control,
lv-shRNA-H19, lv-miR-342-3p inhbitor and lv-shRNA-H19+ miR-342-3p inhbitor group, respectively
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Discussion
In recently reports, H19 exerted two opposite effects
depending on tumor types: it functioned as an oncogene
in ovarian cancer [36], colorectal cancer [27], breast can-
cer [37] and glioblastoma [38]; whereas, it exerted tumor
suppression effects in hepatocellular carcinoma [39], pros-
tate cancer [40] and Wilms’ tumor [41]. In our previous
study, we found that H19 functions as an oncogene in
GBC and promoted cell proliferation by upregulating the
AKT2 expression level in GBC cells, and upregulation of
H19 promoted the epithelial-mesenchymal transition
(EMT) [28, 29]. Based on these previous researches, our
further revealed that H19/miR-343-5p/FOXM1 might be
a potential ceRNA regulatory network in GBC.
To uncover the mechanism of H19 regulation in GBC,
we discovered that H19 shared miR-342-3p response
element with FOXM1, an important oncogene that has
been reported to be associated with many cancers [42–44].
Interestingly, miR-342-3p exerted tumor suppression
effects in GBC, which was consistent with other findings
in lung cancer [45], hepatocellular carcinoma [46] and
cervical cancer [35]. Furthermore, the results of dual-
luciferase reporter assay, RNA-binding protein immuno-
precipitation assay and RNA pull-down assay indicated
that H19 was a target of miR-342-3p.
FOXM1 was known to regulate a transcriptional pro-
gram required for mitotic progression [47]. Numerous
articles have reviewed that FOXM1 function as onco-
gene and could be a therapeutic target in many kinds
of cancer [48, 49]. Our results indicated that down-
regulation of FOXM1 inhibited cell invasion in GBC
cells, which was consistent with others reports [50].
We further defined that down-regulating FOXM1
arrested GBC cells in G0/G1 phase also in accordance
with reports showing that FOXM1 promotes mitotic
gene expression [51]. Previous studies about transcription
regulation signaling pathway suggested that FOXM1
transcriptionally regulated of downstream genes such as
TGF-β/SMAD3/4 to promote cancer metastasis [52]
and induced PRX3 to regulates stemness and survival of
colon cancer cells [53]. For FOXM1 downstream study,
a microarray analysis indicated that LncRNA-FRLnc1
was regulated by FOXM1 [54]. However, regulation by
up-stream factors that activated FOXM1 has remained
enigmatic. Our findings indicate that either in vitro or in
vivo, H19 up-regulation is sufficient to up-regulate
FOXM1 and promotes GBC proliferation.
It is worth noting that the relationship between H19
and FOXM1 depends on miR-342-3p. Our results pro-
posed that H19 functioned as a ceRNA for miR-342-
3p, a new miRNA, to regulate FOXM1 epigenetically.
Previous reports about H19 in post-transcriptional
regulation included that placental specific expression
of miR-675 was encoded by H19 at gestational time
point to target insulin-like growth factor 1 receptor
[55]. Moreover, another reports supported that H19-
derived miR-675 targeting TGF-β signaling [40, 56]
and tumor suppressor RB [57]. We discovered that
knocked down H19 in GBC cell lines increased the
endogenous level of miR-342-3p (Fig. 1d, e), and these
effects were neutralized by exogenous miR-342-3p
inhibitor (Fig. 3a–d). The expression of H19 was not
changed by miR-342-3p mimic or miR-342-3p inhibi-
tor, which indicated that H19 was the upstream of
miR-342-3p. Our study suggests a potential regulation
pathway that involving H19 in both molecular and bio-
logical aspects in GBC.
Conclusions
In conclusion, we suggest a potential ceRNA regulatory
network involving H19 and miR-342-3p in the modula-
tion of FOXM1 expression. This mechanism may con-
tribute to a better understanding of GBC pathogenesis
and provides new therapeutic target as well as prognos-
tic marker in GBC.
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